Recursion Pharmaceuticals Forecast, price target & analysts
Recursion Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Recursion Pharmaceuticals Classifications & Recommendation:
Recursion Pharmaceuticals Price Target
| Target Price | $9.00 |
| Price | $7.67 |
| Potential |
17.34%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Recursion Pharmaceuticals 2026 .
The average Recursion Pharmaceuticals target price is $9.00.
This is
17.34%
register free of charge
$11.00
43.42%
register free of charge
$6.00
21.77%
register free of charge
|
|
| A rating was issued by 7 analysts: 2 Analysts recommend Recursion Pharmaceuticals to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Recursion Pharmaceuticals stock has an average upside potential 2026 of
17.34%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 44.58 | 70.75 |
| 11.90% | 58.70% | |
| EBITDA Margin | -712.43% | -569.32% |
| 25.46% | 20.09% | |
| Net Margin | -1,013.39% | -648.66% |
| 3.82% | 35.99% |
8 Analysts have issued a sales forecast Recursion Pharmaceuticals 2024 . The average Recursion Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Recursion Pharmaceuticals EBITDA forecast 2024. The average Recursion Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Recursion Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Recursion Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.58 | -1.61 |
| 16.18% | 1.90% | |
| P/E | negative | |
| EV/Sales | 37.58 |
2 Analysts have issued a Recursion Pharmaceuticals forecast for earnings per share. The average Recursion Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Recursion Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Recursion Pharmaceuticals...
Current Recursion Pharmaceuticals Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 06 2025 |
| Keybanc | Locked ➜ Locked | Locked | Jan 08 2025 |
| Needham | Locked ➜ Locked | Locked | Dec 11 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 20 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 07 2024 |
| Needham | Locked ➜ Locked | Locked | Sep 04 2024 |
| Jefferies | Locked ➜ Locked | Locked | Sep 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 06 2025 |
|
Locked
Keybanc: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 20 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 07 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Sep 04 2024 |
|
Locked
Jefferies: Locked ➜ Locked
|
Sep 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
